These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. van Loveren-Huyben CM; Engelaar HF; Hermans MB; van der Bom JA; Leering C; Munnichs JM J Am Geriatr Soc; 1984 Aug; 32(8):584-8. PubMed ID: 6379022 [TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of hydergine in Alzheimer's disease. Posner JD; Landsberg L N Engl J Med; 1991 Jan; 324(3):197-8. PubMed ID: 1984200 [No Abstract] [Full Text] [Related]
11. Alzheimer's disease: clinical features and pharmacologic management. Franks AS; Rawls WN Am J Manag Care; 1998 Apr; 4(4):595-604; quiz 606-7. PubMed ID: 10179918 [No Abstract] [Full Text] [Related]
12. Navigating patients and caregivers through the course of Alzheimer's disease. Aupperle PM J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Antuono PG Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110 [TBL] [Abstract][Full Text] [Related]
15. A double-blind evaluation of 'Hydergine' and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Thibault A Curr Med Res Opin; 1974; 2(8):482-7. PubMed ID: 4217240 [No Abstract] [Full Text] [Related]
16. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clipp EC; Moore MJ Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773 [TBL] [Abstract][Full Text] [Related]
17. New developments in the treatment of Alzheimer's disease. J Clin Psychiatry; 2009 Feb; 70(2):281-90. PubMed ID: 19265644 [No Abstract] [Full Text] [Related]